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AntiviralThe latent, constitutively expressed protein RNase L is activated in coxsackievirus and HAV strain 18f infected
FRhK-4 cells. Endogenous oligoadenylate synthetase (OAS) from uninfected and virus infected cell extracts
synthesizes active forms of the triphosphorylated 2-5A oligomer (the only known activator of RNase L) in
vitro and endogenous 2-5A is detected in infected cell extracts. However, only the largest OAS isoform, OAS3,
is readily detected throughout the time course of infection. While IFNβ treatment results in an increase in the
level of all three OAS isoforms in FRhK-4 cells, IFNβ pretreatment does not affect the temporal onset or
enhancement of RNase L activity nor inhibit virus replication. Our results indicate that CVB1 and HAV/18f
activate the 2-5OAS/RNase L pathway in FRhK-4 cells during permissive infection through endogenous levels
of OAS, but contrary to that reported for some picornaviruses, CVB1 and HAV/18f replication is insensitive to
this activated antiviral pathway.
Published by Elsevier Inc.Introduction
Hepatitis A virus (genus Hepatovirus) and coxsackieviruses (genus
Enterovirus) are members of the picornavirus family of RNA viruses
which display contrasting phenotypic effects following infection in
permissive cells. HAV growth is cell type restricted with permissive
replication usually resulting in persistent infection (Hollinger and
Emerson, 2001; Ross et al., 1991). Continuous passage of cell culture
adapted HAV strains results in the emergence of faster growing strains
capable of inducing a cytopathic effect (cpe) during virus replication,
although cpe induction is limited to only a few cell lines such as FRhK-
4 and BSC1 (Anderson, 1987; Brack et al., 1998; Cromeans et al., 1987;
Lemon et al., 1991; Nasser and Metcalf, 1987; Venuti et al., 1985).
Coxsackieviruses are typically cytopathic in a broad host-range of cells
and are generally considered a faster replicating virus than HAV,
although the establishment of a persistent/latent state for coxsack-
ievirus infection has been reported (Pallansch and Roos, 2001;
Whitton, 2002; Zeichhardt and Grunert, 2000; Chehadeh et al.,
2000; Conaldi et al., 1997; Feuer et al., 2004; Heim et al., 1992; Schnurr
and Schmidt, 1984).lka), mona.calvo@fda.hhs.gov
ha.wales@fda.hhs.gov
ami).
Inc.RNA virus infection can result in activation of the 2′-5′oligoadeny-
late synthetase (2-5OAS)/RNase L pathway, and induction of riboso-
mal RNA (rRNA) cleavage is a hallmark indicator of pathway activation
(Cayley et al., 1982; Han et al., 2007; Han and Barton, 2002; Nilsen et
al., 1982; Rice et al., 1984; Scherbik et al., 2006; Silverman et al., 1982,
1983;Wreschner et al., 1981). This pathway is traditionally considered
an essential antiviral mechanism induced in cells in response to
interferon (Ghosh et al., 2000; Hassel et al., 1993; Rysiecki et al., 1989;
Samuel, 2001; Zhou et al., 1998). Two major components of this
pathway are the interferon-inducible enzymes 2-5OAS and RNase L,
whose biochemical and functional properties have been the subject of
numerous reviews (Bisbal and Silverman, 2007; Hovanessian and
Justesen, 2007; Samuel, 2001; Sarkar and Sen, 2004). 2-5OAS is
activated by dsRNA to synthesize a series of 2′-5′ linked oligoadenylic
acid multimers of the general formula pppA(2′p5′A)n (where n≥2)
that, for convenience, is called 2-5A. 5′-phosphorylated trimers (or
higher oligomers) of 2-5A activate the latent endoribonuclease RNase
L. Once bound with 2-5A, RNase L undergoes a conformational change
leading to homodimerization and enzymatic activation. Activated
RNase L has been shown to degrade viral and cellular single-stranded
RNA (ssRNA). Although cellular 2-5OAS andRNase L expressionmaybe
regarded as IFN-inducible, in actuality, cell lines vary with regard to
their endogenous levels and the extent to which these levels increase
following IFN treatment (Hovanessian and Justesen, 2007; Justesen et
al., 2000).
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animal species including human, mouse, rabbit, rat, and pig (reviewed
in Hovanessian and Justesen, 2007; Justesen et al., 2000; and Sarkar
and Sen, 2004). In human cells there are three genes that encode the
three major forms of the enzymes: the 40 and 46 kDa small isoforms
(OAS1), the 69 and 71 kDa medium isoforms (OAS2), and the 100 kDa
large isoform (OAS3). Alternative splicing of OAS1 and OAS2 gene
transcripts yield mRNAs that encode for isoforms whose respective
proteins differ only at their carboxy-terminal regions. Only one mRNA
species has been identiﬁed for human OAS3. While human OAS genes
appear to share certain regulatory elements such as an interferon
responsive element (ISRE), they also appear to contain elements
unique to particular isoforms which account for their differential
response to transcription factors such as NFκB and IL-6 (Justesen et al.,
2000). Indeed, the pattern of both endogenous and IFN-inducible
expression of each isoform can vary with cell type suggesting the
presence of additional regulatory elements that have yet to be fully
elucidated. All three protein isoforms synthesize 2-5A in response to
activation by dsRNA but differ in a number of aspects including the
number of protein units per homo-complex, the activating concentra-
tions of dsRNA and the range of oligomeric 2-5A units synthesized
(Hovanessian and Justesen, 2007; Marie et al., 1997; Player and
Torrence, 1998; Sarkar and Sen, 1998). As 2-5A is the only known
activator of RNase L, its synthesis by dsRNA-activated OAS is presumed
to be a necessary prerequisite for RNase L activation. Synthetic dsRNAs
such as poly (I): poly (C) are useful in the study of 2-5OAS activation
since they are believed to mimic OAS-activating viral dsRNA that
might exist as a consequence of inherent genomic dsRNA structure
(e.g., reovirus) or that may be formed as part of the replication
complex of single-stranded RNA viruses, or as a consequence of
secondary structures generated from viral RNA folding (Gribaudo et
al., 1991; Jacobs and Langland, 1996; Marie et al., 1990; Minks et al.,
1979; Nilsen et al., 1982; Rice et al., 1984). Picornavirus replication has
been reported to be particularly sensitive to inhibition by an activated
2-5OAS/RNase L pathway in an interferon-dependent manner.
However, these studies have been done with only a limited number
of cell lines and picornaviruses (Bisbal and Silverman, 2007; Jacobs
and Langland, 1996; Player and Torrence, 1998; Samuel, 2001). In
contrast to these reports, we have observed the induction of rRNA
cleavage, indicative of activated RNase L, during permissive infection
with either CVB1 or HAV cytopathic strain (18f) in rhesus monkey
kidney cell line (FRhK-4) (Goswami et al., 2004; Kulka et al., 2003).
However, results from these studies also suggested that the activation
of RNase L might be occurring through a non-canonical mechanism
since i) there was a paucity of detectable OAS1 or OAS2 mRNA
expression during HAV infection, ii) activation of the RNase L pathway
(viz. rRNA degradation) did not require pretreatment of infected cells
with interferon, and iii) activated RNase L had little effect on the
production of infectious HAV/18f virus. The results indicated that in
stark contrast to the role of RNase L in other systems, in FRhK-4 cells
infected with HAV/18f, it might actually play a role in the growth and
replication of this cytopathic HAV strain.
The present study was undertaken to determine whether activa-
tion of RNase L during CVB1 or HAV/18f infection in FRhK-4 cells
involves activation of 2-5OAS (i.e., 2-5A synthesis) and whether
activation of the 2-5OAS/RNase L pathway requires interferon. In
addition, we sought to determine whether or not this pathway lacks
the functionality as an antiviral mechanism against CVB1 infection as
we previously reported for HAV/18f infected cells (Goswami et al.,
2004; Kulka et al., 2003). Our results indicate that during either CVB1
or HAV/18f infection: i) endogenous levels of 2-5 OAS, predominantly
consisting of the largest isoformOAS3, are sufﬁcient for induction of 2-
5A synthesis and activation of the 2-5OAS/RNase L pathway by virus
infection; ii) interferon plays little if any role in the activation of the
pathway; iii) activation of RNase L does not result in substantial viral
RNA degradation (Kulka et al., 2003) or viral protein synthesisinhibition; and iv) high yields of infectious virus are obtained despite
RNase L activation. We conclude that activation of the canonical 2-
5OAS/RNase L antiviral pathway occurs, but does not function as part
of a cellular defense mechanism against CVB1 or HAV infection in
these cells.
Results
Induction of rRNA cleavage in FRhK-4 cells during CVB1 or HAV/18f
infection
We have previously shown that FRhK-4 cells are permissive for
CVB1 and HAV replication and that rRNA cleavage in these cells can be
detected at 6–7 h pi or 24 h pi with either CVB1 or HAV/18f
respectively without prior treatment with IFN (Kulka et al., 2003). The
pattern of RNA cleavage was characteristic of an activated RNase L
(Cayley et al., 1982; Goswami and Sharma,1984; Goswami et al., 2004;
Han et al., 2007; Han and Barton, 2002; Kulka et al., 2003; Nilsen et al.,
1982; Rice et al., 1984; Scherbik et al., 2006; Silverman et al., 1982,
1983; Wreschner et al., 1981). In the current study, we used agarose
gel electrophoresis to monitor rRNA cleavage as an indicator of RNase
L activation and western blot analysis to monitor virus capsid
expression as an indicator of virus replication in 2–8 h CVB1 infected,
16–48 h HAV/18f infected and HAV/HM 175 clone 1 persistently
(100–150 d pi) infected FRhK-4 cells. Mock infected cultures served as
negative controls in both rRNA degradation andwestern blot analyses.
In either CVB1 or HAV/18f infected cell extracts, fully processed
virus capsid protein is detected and increases with the time of
infection indicating successful virus infection and replication in these
cells (Fig. 1, panels A and B). As previously reported, rRNA cleavage is
readily observed in CVB1 infected cells at 8 h pi and in HAV/18f
infected cells at 24 h pi (Kulka et al., 2003). However, in this study we
observed that the appearance of rRNA cleavage during HAV/18f
infection can be detected as early as 16 h pi, albeit with a lesser
intensity than observed at 24 h pi (Fig. 1D). HAV/18f precursor and
fully processed capsid proteins are detected at b16 h pi in the absence
of rRNA cleavage (data not shown). The results indicate that the
cytolytic viruses CVB1 and HAV/18f induce rRNA degradation around
the time of, or prior to, the onset of cytopathic changes (cpe observed
at≥8 h pi for CVB1 and 36–48 h pi for HAV/18f) and virus replication–
as measured by a marked increase in capsid protein expression–
appears unaffected by RNase L activation in these cells (Fig. 1, panels A
and B). As a positive control for induction of RNaseL-dependent rRNA
cleavage, FRhK-4 cells transfected with dsRNA resulted in rRNA
cleavage with a cleavage pattern similar to those observed in either
CVB1 or HAV/18f infected cells (Fig. 1 panels C–E). These results
suggest that in FRhK-4 cells, both viral-induced and dsRNA-induced
cleavage of rRNA occur by a mechanism that is indicative of RNase L
activation. The noncytolytic HAV strain HM175 establishes a persistent
infection in these cells without activation of RNase L activity, despite
the presence of viral capsid proteins (Fig. 1, panels F and G), and
therefore, viral mRNA as well.
RNase L protein is present during CVB1 or HAV infection in FRhK-4 cells
The cleavage of rRNAs observed following infection with either
CVB1 or HAV/18f indicates that the normally latent, endogenous
RNase L was activated during infection with these viruses in FRhK-4
cells (Fig. 1, panels C and D). Using PCR primers that target sequences
ﬂanking the entire RNase L coding region, we conﬁrmed by RT-PCR
that an RNase L mRNA similar to that of human origin is constitutively
expressed in FRhK-4 cells (Fig. 2A). Western blot analyses using RNase
L speciﬁc antibody revealed readily detectable levels of RNase L
protein (80 kDa) in FRhK-4 cells as well as in 293 cells (Fig. 2B). Thus,
RNase L from monkey and human cells is similar with respect to the
size of its mRNAs and proteins, and activation following dsRNA
Fig. 1. Analysis of virus capsid expression and cellular rRNA cleavage in FRhK-4 cells infected with CVB1, HAV/18f or HAV clone 1. (A, B, F) Protein extracts (35 μg) were analyzed for
speciﬁc virus capsid protein synthesis in mock or CVB1 infected, 2–8 h post-infection (h pi) (A), mock or HAV/18f infected, 16–48 h pi (B) FRhK-4 cells, and uninfected or HAV clone
1 persistently infected FRhK-4 cells (F), by western blot analysis using anti-CVB1 (A) or anti-HAV VP1 (B and F) antibody. Cells were infected at an moi of 8–10 for this and all
experiments. Viral capsid proteins are identiﬁed with arrows. (C–E, G) Total cytoplasmic RNA (4 μg) extracts from mock or CVB1 infected, 2–8 h pi (C), mock or HAV/18f infected,
16–48 h pi (D), mock or dsRNA transfected (E), and uninfected or HAV clone 1 persistently infected (G) FRhK-4 cells were analyzed for RNA degradation by agarose gel electrophoresis
(Goswami et al., 2004). The 28S and 18S rRNAs are identiﬁed with arrows. Cleavage of rRNA is not observed in mock infected, uninfected or HAV clone 1 infected cells.
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present under conditions that induce rRNA cleavage, we investigated
the status of RNase L protein expression in CVB1 as well as HAV/18f
infected FRhK-4 cells. As shown in Fig. 2C, CVB1 infection does not
signiﬁcantly alter (≤2-fold reduction by densitometric scanning) the
overall level of RNase L protein compared tomock infected cells. These
results indicate that RNase L is present both before and during CVB1
infection despite induction of host protein synthesis shut-off, rRNA
cleavage, and a decrease in the level of some host mRNAs in these
infected cells (Kulka et al., 2003).
Unlike other members of the picornavirus family such as
coxsackievirus, a speciﬁc virus-mediated host (translation) shut-off
function has not been identiﬁed for HAV. However, HAV/18f infection
does induce rRNA cleavage as well as a reduction in the level of hostmRNAs such as actin and GAPDH (Kulka et al., 2003). Despite these
events, HAV/18f infection does not result in any signiﬁcant reduction
of RNase L mRNA levels in FRhK-4 cells (Goswami et al., 2004), and as
shown in Fig. 2C, HAV/18f infection has no signiﬁcant effect on the
steady state levels of RNase L protein compared tomock infected cells,
even at 48 h pi that is N30 h after initial detection of rRNA cleavage
(see Fig. 1D). RNase L protein is also present in poly(I):poly(C) dsRNA
transfected FRhK-4 cells (Fig. 2D) and at levels similar (within a 2-fold
difference) to either non-transfected or transfected control cells,
although RNA cleavage is quite apparent at this point (Fig. 1E). The
results in Fig. 2 conclusively show that RNase L (both protein and
mRNA) is present in cells following CVB1 or HAV/18f infection as well
as during treatment with dsRNA, and is therefore available for
activation. Interestingly, the reason for the absence of rRNA cleavage
Table 1
Amino acid comparison between immunizing OAS peptide and homologous sequences
in human and rhesus monkey OAS1, OAS2, and OAS3.






OAS1 EKYLRRQLTKP/RPVILDPAD 100% Exon D/exon E NM016816a
GKYLSRQLRKP/RPVILVPAD 80% XM001110682b
OAS2 RNILLHQLQSA/RPVILDPVD 53% Exon D1/exon E1 NM016818a
RKFLLSQLQKT/RPVILDPAE 65% Exon D2/exon E2
RNILLPQLQSA/RPVILDPTD 53% Exon D1/exon E1 XM001110954b
PKFLLSQLQKT/RPVILDPAE 65% Exon D2/exon E2
OAS3 GQFLQRQLKRP/RPVILDPAD 70% Exon D1/exon E1 BC113746a
RMHLLGQLRKP/RPLVLDPAD 60% Exon D2/exon E2
GDFLKQQLQKP/RPIILDPAD 65% Exon D3/exon E3
GQFLQRQLERP/RPVILDPAD 70% Exon D1/exon E1 XM001110841b
RMHLLGQLRKP/RPLVLDPAD 60% Exon D2/exon E2
GDFLKQQLQKP/RPIILDPAD 65% Exon D3/exon E3
The OAS peptide used for immunization was (C)EKYLRRQLTKPRPVILDPAD as described
under Materials and methods and based on peptide B as described in Chebath et al.
(1987a). This peptide immunogen has 100% identity with human OAS1 amino acids
encoded at the exon D/exon E junction. Alignment of human amino acid sequences at
the exon boundaries for human (a) OAS isoforms was based on Justesen et al. (2000)
while alignment of rhesus monkey (b) OAS isoforms was accomplished following
sequence comparison between human and available rhesus monkey sequences. The
GenBank accession numbers for OAS 1, OAS2, and OAS3 sequences are given, and amino
acids identical to those in the immunizing peptide are underlined.
Fig. 2. RNase L expression in CVB1 or HAV infected, or dsRNA transfected FRhK-4 cells,
and in uninfected human cells. (A) Total cytoplasmic RNA (1 μg) from either FRhK-4 or
293 (human) cells was subjected to reverse transcription using oligo d(T)15 as primer
for cDNA synthesis followed by PCR (30 cycles) using primers speciﬁc for RNase L
followed by agarose gel electrophoresis. The positions of the RNase L amplicons are
indicated by an arrow. (B–D) Protein extracts (35 μg) were analyzed for RNase L
expression from routinely sub-cultured FRhK-4 or 293 cells (B); mock, CVB1, or HAV/
18f infected FRhK-4 cells; routinely sub-cultured (lane RC) or HAV clone 1 persistently
infected FRhK-4 cells; 12 h IFNβ (1000 U/ml) treated FRhK-4 cells (C); or 24 h non-
transfected (lane NTC), mock or dsRNA transfected FRhK-4 cells (D) by western blot
analysis using anti-RNase L antibody to detect the 80 kDa RNase L protein (arrow).
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to an absence of RNase L or virus speciﬁc proteins as they are readily
detected by western blot (Figs. 1A and 2C).
Treatment with either interferon or dsRNA, but not CVB1 or HAV/18f
infection, induces expression of 2-5OAS protein in FRhK-4 cells
The transcriptional activation of cellular genes involved in an
antiviral response to virus infection may be either through prior
induction of interferon or through direct activation of transcription
factors (Samuel, 2001; Sarkar and Sen, 2004). The 2-5OAS/RNase L
activation pathway is a major antiviral pathway that may be activated
by virus infection/viral dsRNA, either directly or indirectly through
interferon. Regardless of whether 2-5OAS levels are induced by
interferon, virus infection or dsRNA treatment, these enzymes
ultimately require dsRNA for their enzymatic activation and synthesis
of 2-5A oligonucleotides that go on to activate endogenous, latent
RNase L (Bisbal and Silverman, 2007; Player and Torrence, 1998;
Samuel, 2001). Since the induction of rRNA degradation during CVB1
or HAV/18f infection is indicative of activation of the 2-5OAS/RNase Lpathway, we sought to examine whether activation might be
associated with an increase in 2-5OAS expression during virus
infection of FRhK-4.
In order to investigate 2-5OAS protein expression in FRhK-4 cells,
we raised antiserum in rabbits against a 2-5OAS peptide whose
sequence was based on the peptide B sequence derived from human
2-5OAS isoform 1 as described by Chebath et al. (1987a). As shown in
Table 1, the relative position of the homologous sequences deﬁned by
the peptide is the same for both human and rhesus monkey 2-5OAS,
that is, at the exon D/exon E boundary within the single (OAS1) and
repeated units (OAS2 and OAS3). The percent sequence identity
between the immunizing peptide and the homologous sequence in
rhesus monkey OAS1 is 80%. The percent identity between the
homologous regions of human OAS2 and OAS3 and the peptide
immunogen ranges from 55 to 65% and 60 to 70%, respectively, and is
the same between the peptide and the homologous regions of rhesus
monkey OAS2 and OAS3. Since these amino acids are also highly
conserved between human and rhesus monkey, we predicted that the
polyclonal rabbit antiserum would recognize the epitopes in rhesus
monkey 2-5OAS proteins.
Since the data in Figs. 1 and 2 suggest that dsRNA induces rRNA
degradation via activation of RNase L in FRhK-4 cells, and therefore
activation of the 2-5OAS, we investigated the effect of dsRNA
treatment on 2-5OAS protein expression in these cells. While
transfection in the absence of dsRNA treatment appears to have
some negative effect on the constitutive levels of OAS3, a dramatic
increase in the level of OAS3 and OAS2 proteins is observed at 24 h
post-dsRNA transfection when compared to either the mock-trans-
fected or non-transfected FRhK-4 cells (Fig. 3A). As shown in Fig. 3
(panels A–D), extracts from either untreated or mock infected FRhK-4
cells reveal that these cells contain constitutive levels of OAS3 but no
detectable levels of either the OAS1 or OAS2 protein. Since we have
previously reported that IFNβ treatment induces expression of OAS2
mRNA in FRhK-4 cells (Goswami et al., 2004), we included an analysis
of the effect of IFNβ treatment as an additional positive control for
detection of inducible OAS protein expression. FRhK-4 cells were
treated for 2 h and 12 h with 1000 U/ml IFNβ prior to analysis of OAS
protein expression bywestern blot. As observed for dsRNA transfected
cells, increased expression of OAS2 and OAS3 was detected following
IFN treatment (12 h) while OAS1 protein was not detected (Fig. 3B),
conﬁrming the sensitivity of these cells to IFN. These results are
consistent with the interpretation that OAS expression in FRhK-4 cells
Fig. 3. The effect of CVB1 or HAV infection, IFNβ treatment, or dsRNA on OAS protein expression in FRhK-4 cells. Protein extracts (35 μg) were analyzed for OAS protein expression in
24 h non-transfected (lane NTC), mock or dsRNA 24 h-transfected (A), non-treated or IFNβ (1000 U/ml) 2 or 12 h treated (B), uninfected or HAV clone 1 persistently infected (B),
mock or CVB1, 2–8 h infected (C), mock or HAV 18f, 16–48 h infected (D) FRhK-4 cells by western blot analysis using afﬁnity puriﬁed anti-OAS antibody. The blots were stripped,
washed and re-probed with anti-actin antibody (A–D, lower panels). OAS2 (69/71 kDa) and OAS3 (100 kDa) are identiﬁed with arrows, OAS1 protein expression was not detected.
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mechanism (Geiss et al., 2001; Hovanessian and Justesen, 2007; Player
and Torrence, 1998; Sarkar and Sen, 2004; Samuel, 2001).
We next sought to determinewhether induction of OAS expression
occurs in either CVB1 or HAV infected cells. As shown in Fig. 3C,
western blot analysis of protein extracts from 2 to 8 h mock infected
FRhK-4 cells reveals a constitutive level of expression of the largest
isoform, OAS3, which remains relatively unchanged throughout the
period of mock infection and is similar to that observed in untreated
FRhK-4 cells (Fig. 3, panels A and B). However, only OAS3 is detectable
throughout CVB1 infection and a decrease in the level of OAS3
expression is observed at 8 h pi (Fig. 3C). All blots were stripped and
re-probed with anti-actin antibody to conﬁrm equivalent loading of
samples since actin protein levels are not signiﬁcantly affected by
either CVB1 or HAV infection in FRhK-4 cells (Goswami et al., 2004;
Kulka et al., 2003). The decrease in the level of OAS3 protein is likely
due, at least in part, to host protein synthesis shut-off by CVB1 in these
cells (Kulka et al., 2003).
The apparent activation of the 2-5OAS/RNase L pathway in the
absence of induction of 2-5OAS protein expression in FRhK-4 cells was
not unique to CVB1 since infection with a genetically distant memberof the same virus Picornaviridae family, HAV/18f, yielded similar
results. As shown in Fig. 3D, constitutive levels of OAS3 protein remain
relatively unchanged throughout the period of mock infection (16–
24 h) and only OAS3 is detected throughout the period of HAV/18f
infection, even as late as 48 h pi when rRNA degradation is readily
detected (Fig. 1D). Re-probing with anti-actin conﬁrms equivalent
loading of samples and therefore, the absence of any increase in the
level OAS3 protein during HAV/18f infection. Indeed, there is some
apparent decrease in the level of OAS3 observed at 24–48 h pi thatmay
be the result of ongoing rRNA degradation. In persistently infected
clone 1 cells, only the OAS3 protein is constitutively expressed and at
levels similar to those detected in uninfected FRhK-4 cells (Fig. 3B). The
lack of rRNA degradation in these persistently infected cells, therefore,
is not due to a lack of either OAS or RNase L protein expression.
Interferon, but not CVB1 or HAV/18f, induces 2-5OAS mRNA expression
in FRhK-4 cells
Since we could not exclude the possibility that either CVB1 or HAV
(acute or persistent) infectionmay induce OAS1 or OAS2 expression at
levels below the detection limit by western blot, RT-PCR was used to
174 M. Kulka et al. / Virology 388 (2009) 169–184examine induction of OAS expression at the level of mRNA. By
applying RT-PCR using PCR primers based on the design and
application by Takahashi et al. (2002) for detection of human 2-
5OAS mRNA isoforms, Goswami et al. (2004) previously revealed the
absence of detectable OAS1 and OAS2 mRNA in HAV infected FRhK-4
cells although the induction OAS2 mRNA levels was detected
following IFNβ pretreatment. In the current investigation we focused
on the application of rhesus monkey 2-5OAS speciﬁc primers for
targeted ampliﬁcation of each 2-5OAS isoform in order to study the
differential expression of all 2-5OAS isoforms in response to CVB1 or
HAV infection in FRhK-4 cells. Table 2 lists the individual primer pairs,
the relative 2-5OAS mRNA nucleotide positions targeted by each
primer, and the targeted exon and predicted amplicon size for each
rhesus monkey primer pair.
Sincewestern blot analysis failed to detect OAS1 and OAS2 proteins
in virus infected extracts (Fig. 3, panels C and D), the PCR ampliﬁcation
of OAS1, OAS2, and OAS3 cDNAs was completed using 35 cycles in
order to maximize detection of anticipated low basal levels of OAS1
and 2 mRNAs in these samples. RNA from control, 2 h and 12 h IFNβ
(1000 U/ml) treated FRhK-4 cells was obtained for initial analysis of
induction of OAS mRNA expression by RT-PCR and Fig. 4A conﬁrms
that IFNβ treatment alone does not activate the 2-5OAS/RNase L
pathway in these cells despite induction in the level of OAS2 and OAS3
proteins (Fig. 3B). As shown in Fig. 4B (upper left and lower left
panels), treatment of FRhK-4 cells with IFNβ (1000 U/ml) effects an
increase in both OAS1 and OAS 2 mRNA above basal levels barely
detected in untreated (12 h) FRhK-4 cells, with the highest levels
observed at 12 h post-IFNβ treatment. The constitutive level of OAS3
mRNA appears greater than that for either OAS1 or OAS2 mRNAs (Fig.
4B) in untreated cells and no signiﬁcant increase in OAS3 mRNA
expression was observed following IFNβ treatment (Fig. 4B, upper
right panel). Since 12 h IFNβ treatment resulted in an increase in the
level of OAS3 protein, we investigated whether 35 cycles of
ampliﬁcation may have obscured induction of OAS3 mRNA expression
by repeating the RT-PCR using 25 cycles of PCR ampliﬁcation. As
shown in Fig. 4B (lower right panel), induction of OAS3 mRNA is
evident following 12 h IFNβ treatment when RT-PCR completed at a
reduced number of PCR cycles. The results indicate that IFNβ induces
expression of all three OAS mRNA isoforms in FRhK-4 cells and, with
the exception of OAS1, the overall pattern and time course of OAS
mRNA induction is concordant with the pattern and time course of
induction of OAS protein expression (Fig. 3B versus Fig. 4B). The
absence of detectable OAS1 protein following IFNβ treatment, there-
fore, may simply be a function of the level of sensitivity of detection by
western blot analysis.
In CVB1 infected cells, there is no detectable induction of any OAS
mRNA (Fig. 4C) over a 2–8 h infection period. This is not due to PCRTable 2
PCR primers for RT-PCR analysis of OAS mRNA expression in FRhK-4 cells.
OAS cDNAa Primer pairb Primer sequenceb
OAS1 Rmk OAS1s 5′ ACAGCTGGAAGCCTGTCAAAG 3′
Rmk OAS1asb 5′ GAAATCTGTTTCCGTGCTCCC 3′
OAS2 Rmk OAS2s 5′ GATGAGACCATCAGGAACATCC 3′
Rmk OAS2as 5′ CCTTGATGATTCTGTACCGCTC 3′
OAS3 Rmk OAS3sb 5′ GCCTGCTTTCTGAGTAGAGATG 3′
Rmk OAS3asb 5′ GGAGACTTCAAACTTGACCTCG 3′
a Rhesus monkey OAS isoform cDNAs targeted by the respective primer pairs whose nuc
OAS2, and OAS3 sequences are XM001110682, XM001110954, and XM001110841, respective
b Sense (s) and antisense (as) PCR primer pairs, and their respective nucleotide seque
transcription using an oligo(dT)15 primer. GCGWisconsin programs BestFit and GAP were u
identity with the non-targeted isoforms of OAS.
c OAS mRNA nucleotide positions targeted by the sense and antisense primers where nu
d The OAS mRNA exon containing the nucleotide sequence targeted by each primer. Exon
e The predicted size in base pairs (bp) of an amplicon generated following RT-PCR ampliﬁc
either 2mMMgCl (for OAS3) or 3mMMgCl (for OAS1 and 2) with cycling parameters of 94 °C
or 35 cycles; 72 °C [10 min] extension; 4 °C soak.failure since RT-PCR of RNA from 12 h IFNβ treated FRhK-4 cells,
included in each analysis as a positive control, yielded readily
detectable OAS1 and OAS2 amplicons. As compared to mock infected
cells, OAS1 and OAS2 mRNAs remain at basal (barely visible) levels.
There appears to be some decrease in the level of OAS3mRNA in CVB1
8 h infected FRhK-4 cells, which may be due in part to the induction of
RNA degradation (Fig. 1C). Nevertheless, there remains a readily
detectable level of OAS3mRNA in CVB1 infected cells. As shown in Fig.
4D, the results of RT-PCR on RNA from HAV/18f 16–24 h pi cells
compared tomock infected cells gave results similar to those obtained
from CVB1 infected cells whereby there is an absence of OAS1 and
OAS2 mRNA induction above very low basal (to undetectable) levels
and a high level of OAS3 mRNA constitutive expression that remains
relatively unchanged during HAV/18f infection. The pattern of OAS3
mRNA expression parallels the proﬁle of 2-5OAS protein expression in
either CVB1 or HAV/18f infected cells. It is interesting to note that the
proﬁle of 2-5OAS mRNA expression in persistently infected HAV clone
1 cells (Fig. 4B, upper right and left, and lower left panels) is also
similar to that from either CVB1 or HAV/18f infected FRhK-4 cells,
supporting the conclusion that the lack of rRNA degradation in these
infected cells (Fig. 1G) is not due to inhibition of either 2-5OAS protein
or RNase L expression. Collectively, the data indicate that the lack of
induction of OAS protein and mRNA expression in either CVB1 or
HAV/18f infected FRhK-4 cells is not due to a cellular defect since both
dsRNA and IFN induce expression of OAS protein and mRNA in these
cells.
Interferon synthesis is not detected in CVB1 infected FRhK-4 cells
While IFN is not produced in response to either acute or persistent
HAV infection in cell culture (Brack et al., 2002; Goswami et al., 2004;
Kulka et al., 2003; Vallbracht et al., 1984, 1985), the production of
interferon has been reported for coxsackievirus infected cell cultures
and plays a role in response to infection in vivo (Chehadeh et al., 2000;
Conaldi et al., 1997; Nakayama et al., 1989; Wessely et al., 2001).
Interestingly, induction of mRNAs for all OAS isoforms occurs
following IFNβ treatment (Figs. 3B and 4B), but there is an absence
of OAS mRNA or protein induction during CVB1 infection in FRhK-4
cells (Figs. 3C and 4C). These results suggest a lack of interferon
synthesis during virus infection in these cells. In support of this
interpretation, phosphorylation of STAT-1, a hallmark cellular
response to the presence of extracellular IFN (Samuel, 2001), occurs
in response to treatment with either IFNα or IFNβ, but not to CVB1
infection in FRhK-4 cells (Goswami et al., 2004; Kulka et al., 2003).
Furthermore, FRhK-4 cells are permissive for CVB1 replication when
infected at either high (moi=10) or low moi (moi=0.05). This also
suggests an absence of interferon production during CVB1 infectionNucleotide positionc Targeted exond Amplicon sizee
+312 to +332 B 436 bp
+747 to +727 D
+817 to +838 D1 484 bp
+1300 to +1279 B2
+2179 to +2200 E2 411 bp
+2589 to +2568 B3
leotide sequences were obtained from GenBank; accession numbers for isoforms OAS1,
ly.
nces, used to amplify the speciﬁc OAS isoform from FRhK-4 cells following reverse
sed to conﬁrm identity of each primer pair against the target sequence as well as non-
mbering starts (+1) at the ﬁrst nucleotide of the initiation codon.
assignment was based on the alignment of Justesen et al. (2000).
ation of the OASmRNA sequencewith the targeting primer pair. PCR reactions contained
[90s], 62 °C (OAS1 primers) or 64 °C (OAS2 and OAS3 primers) [90s], 72 °C [120s] for 25
Fig. 4. The effect of CVB1 or HAV infection, or IFNβ treatment on OAS mRNA expression in FRhK-4 cells. (A) Total cytoplasmic RNA (4 μg) from untreated (12 h) or treated with
1000 U/ml human IFNβ for 2 or 12 h FRhK-4 cells was analyzed as in Fig. 1. No rRNA degradation was observed. (B–D) Total cytoplasmic RNA (1 μg) from untreated or human IFNβ
(1000 U/ml) treated, 2 or 12 h (B), uninfected or HAV clone 1 infected (B), mock or CVB1 infected, 2–8 h (C), mock or HAV 18f infected, 16–48 h (D), FRhK-4 cells was subjected to
reverse transcription using oligo d(T)15 as primer for cDNA synthesis followed by PCR [35 cycles (or 25 cycles, panel B, bottom right image)] using primers speciﬁc for rhesus monkey
OAS isoforms 1, 2 and 3, followed by agarose gel electrophoresis (Goswami et al., 2004). RNA from FRhK-4 cells treated for 12 h with human IFNβ (1000 U/ml) was analyzed
simultaneously with RNA frommock and infected cells as a positive control, and sample-minus PCR (nc) reactions were included as negative controls. The position of OAS amplicons
are indicated with arrows. The predicted amplicon sizes for rhesus monkey OAS1, OAS2, and OAS3 are 436 bp, 484 bp, and 411 bp, respectively.
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occurs during the initial round of infection and replication to
subsequently protect uninfected cells from subsequent infection. In
contrast, FRhK-4 cells are not defective for synthesis of biologically
active IFN since dsRNA treatment results in the induction of IFNβ
mRNA synthesis (Goswami et al., 2004) and strong phosphorylation
of STAT-1 (Fig. 5A).
We sought to directly investigate the apparent lack of interferon
production by examining IFNβ mRNA expression during CVB1
infection. RNA was obtained from mock or CVB1 infected FRhK-4
cells at 2–8 h pi and analyzed by RT-PCR. Cellular RNA from dsRNA
transfected FRhK-4 cells was included as a positive control for IFNβ
mRNA expression since dsRNA is a well-known inducer of IFN
synthesis (Sarkar and Sen, 2004). As shown in Fig. 5B, induction of
IFNβ expression was not detected in CVB1 infected cells while there
was a strong induction of IFNβmRNA following dsRNA treatment. The
absence of detectable IFNβ expression in mock or CVB1 infected cells
was not due to a failure of the RT reaction since β-actin was readily
ampliﬁed in these samples (Fig. 5B). Taken together with our previousﬁndings (Goswami et al., 2004; Kulka et al., 2003), these results
suggest that there is no signiﬁcant induction/production of IFN
following CVB1 infection, and therefore, IFN does not appear to play
a role as an antiviral during the productive replication of CVB1 virus in
FRhK-4 cells.
The lack of IFN synthesis but apparent activation of the 2-5OAS/
RNase L during CVB1, or HAV/18f, infection led us to conﬁrm
whether dsRNA of viral origin is made in these cells. We used strand
speciﬁc RT-PCR to detect synthesis of viral negative strand genomic
RNA that is considered to be important for the formation of viral
dsRNA structures necessary for the activation of the 2-5OAS/RNase
L pathway and involved in induction of IFN synthesis in picornavirus
infected cells (Barral et al., 2007; Gribaudo et al., 1991; Jacobs and
Langland, 1996; Minks et al., 1979; Racaniello, 2001; Sarkar and Sen,
2004; Yang et al., 2007). As shown in Figs. 6A and B, both negative
and positive strand RNA was readily detected in both CVB1 and
HAV/18f infected cells relatively early in infection thereby providing
a potential source of viral RNA for 2-5OAS/RNase L pathway
activation.
Fig. 5. The effect of dsRNA or CVB1 infection on IFNβ mRNA expression, and dsRNA on STAT-1 phosphorylation in FRhK-4 cells. (A) Nuclear (top panel) and cytoplasmic (bottom
panel) protein extracts were obtained from mock (−) or dsRNA (+) transfected (24 h) FRhK-4 cells using the Nuclei EZ kit (Sigma) according to manufacturer's instructions and
subjected to Western blot analysis using antibody to either phosphoY701-STAT-1 (top panel) or STAT-1 (bottom panel). (B) Total cytoplasmic RNA (1 μg) from either mock or dsRNA
transfected (24 h), or mock or 2–8 h CVB1 infected FRhK-4 cells was subjected to reverse transcription using oligo d(T)15 as primer for cDNA synthesis followed by PCR using primers
speciﬁc for IFNβ (top panel) or β-actin (bottom panel) and agarose gel electrophoresis as previously described (Goswami et al., 2004). The positions of the IFNβ amplicon (552 bp)
and β-actin amplicon (285 bp) are indicated by arrows. RT-minus (rnc) and sample-minus (pnc) PCR reactions were included as negative controls.
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induction of rRNA degradation in CVB1 infected FRhK-4 cells
The protective role of interferon in CV infection has been
investigated by a number of laboratories, which have reported that
coxsackievirus replication in cultured fetal heart, myocardial ﬁbro-
blast and pancreatic islet cells can be inhibited by interferon
(Flodstrom-Tullberg et al., 2005; Heim et al., 1992; Hultcrantz et al.,Fig. 6. Detection of viral negative strand RNA synthesis by strand-selective RT-PCR. (A)
Cytoplasmic RNA was isolated from HAV/18f or clone 1 (Cln 1) infected FRhK-4 cells
after acute infection (24 or 48 h) or persistent infection (28d). Reverse transcription
was carried out using either the sense or the antisense primer to prime cDNA synthesis,
followed by PCR ampliﬁcation as described in Materials and methods. The presence of
negative strand viral RNA (an indicator of RNA replication) is detected only in acute
infectionwith the 18f virus and persistent infection by clone 1 virus (28d). The presence
of viral positive strand RNA following acute infectionwith clone 1 virus (48 h) indicates
the presence of input viral genome. (B) Cytoplasmic RNA was isolated from mock or
CBV1 infected (2–8 h) FRhK-4 cells for reverse transcription with sense or antisense
primers followed by PCR as described in Materials and methods. The presence of both
positive and negative strand synthesis is detected throughout the time period of CVB1
infection.2007; Kandolf et al., 1985). We sought, therefore, to investigate
whether IFNmay play a protective role as an antiviral in CVB1 infected
FRhK-4 cells via an interferon-mediated enhancement of rRNA
degradation, inhibition of viral protein synthesis, or inhibition of
virus replication following exogenous IFNβ pretreatment of virus
infected cells. As shown in Fig. 7A, IFNβ pretreatment (1000 U/ml,
12 h) does not affect the temporal onset or severity of rRNA
degradation during CVB1 infection (2–8 h pi) even though the same
dosage and time of IFNβ treatment has been shown to elevate levels of
all three isoforms of OAS (Figs. 3B and 4B). This absence of an apparent
IFN effect is not due to an inhibition of CVB1 replication since the level
of 35S-methionine incorporation, and the pattern of labeled viral
protein expression in CVB1 infected cells, were unaffected by IFNβ
pretreatment as determined at 8 h pi after pulse-labeling CVB1
infected FRhK-4 cells pretreated (12 h) or not with IFNβ (Fig. 7B). We
further conﬁrmed the absence of an interferon effect on CVB1
replication by analysis of viral titers in CVB1 8 h infected (moi=10)
FRhK-4 cells pretreated or not for 12 h with 1000 U/ml IFNβ.
Pretreatment with IFNβ had no signiﬁcant effect (as determined by
student's t-test, one-tailed) on virus replication since virus titers of
8.72±0.12 log10 TCID50/ml and 8.13±0.24 log10 TCID50/ml (average
of two experiments, duplicate samples per time point±1 standard
deviation) were achieved in infected cells without or with IFNβ
pretreatment, respectively. In addition, we observed that IFNβ
pretreatment had no effect on the time of onset (7–8 h pi) or severity
of cpe (nearly all cells ﬂoating at 14–16 h pi) between CVB1 infected
cells (moi=10) pretreated (12 h) or not with IFNβ (1000 U/ml). Our
ﬁndings suggest, therefore, that IFNβ does not play a signiﬁcant
protective role as an antiviral compound against CVB1 in these cells
even though it functions to elevate components of the 2-5OAS/RNase
L antiviral pathway.
Taken in toto, the data in Figs. 1–7 suggest that existing levels of
2-5OAS during CVB1 or HAV/18f infection are sufﬁcient for activation
by these viruses, and any increase in 2-5OAS levels prior to infection
(e.g., following interferon treatment) does not enhance 2-5OAS
activity, or the downstream events of OAS activation, i.e. RNase L
activation and RNA cleavage.
Endogenous 2-5 OAS is functionally active in CVB1 and HAV/18f infected
FRhK-4 cells
Since our results indicate that activation of the 2-5OAS/RNase L
pathway occurs in virus infected FRhK-4 cells containing constitutive
levels of 2-5OAS, we sought to determine whether endogenous
Fig. 7. The effect of IFNβ pretreatment on rRNA degradation and viral protein synthesis in CVB1 infected FRhK-4 cells. (A) Total cytoplasmic RNA extracts (4 μg) from CVB1 infected
FRhK-4 cells at 2, 6 and 8 h pi, treated or not 12 h with 1000 U/ml human IFNβ prior to infectionwere analyzed for RNA degradation as in Fig. 1. The 28S and 18S rRNAs are identiﬁed
with arrows. Pretreatment with IFNβ has no effect on the induction of rRNA degradation in FRhK-4 cells following CVB1 infection. (B) FRhK-4 cells were grown in 25 cm2 ﬂasks and
12 h prior to virus infection cells were treated or notwith growthmedia containing 1000 U/ml human interferon β (Sigma-Aldrich). Cells weremock or CVB1 infected and labeled for
2 h beginning at 6 h pi with 50 μCi/ml of 35S-methionine (GE Life Sciences) in methionine-free medium (EMEM, Sigma) supplemented with 5% dialyzed FBS (Sigma) following a
30 min pre-incubation in methionine-free medium. Labeled protein extracts (200,000 cpm per lane) were subjected to SDS-PAGE, the gel was ﬁxed and treated with Amplify for
signal enhancement according to manufacturer's instructions (Amersham Pharmacia Biotech Inc., Piscataway, NJ), then soaked in water containing 20% ethanol and 10% glycerol for
30 min prior to overnight drying between cellophane sheets (Diversiﬁed Biotech, Boston, MA). The dried gel was exposed to a phosphorimager screen prior to analysis using the
Typhoon scanner (Molecular Dynamics Inc., Sunnyvale, CA).
Table 3
Detection of 2-5A in CVB1 and HAV/18f infected cell extracts.
Lysatea 2-5A pmol/dLd
Extract (sample)b Dilutionc
177M. Kulka et al. / Virology 388 (2009) 169–1842-5OAS is capable of producing authentic 2-5A. Cell extracts were
obtained from CVB1 or HAV/18f infected, or interferon treated FRhK-4
cells, and analyzed for their capability of synthesizing 2-5A in vitro
based onpreviously publishedmethods that employ a synthetic dsRNA
matrix, poly(I):poly(C)-agarose, for afﬁnity capture and subsequent
activation of OAS (Revel et al., 1981; Sarkar and Sen, 1998). Analysis of
product formation was accomplished by denaturing polyacrylamide
gel electrophoresis (Miele et al., 1991). Rabbit reticulocyte (nuclease
treated) lysate was used as a positive source of endogenous OAS and a
control for in vitro synthesis of 2-5A (Hovanessian and Kerr, 1978;
Suhadolnik et al., 1983; Wu et al., 1985). As shown in Fig. 8, panel B
(lanes RL), the synthesis of 2-5A from reticulocyte lysates is quite
robust and results in the formation of the 2-5 A oligomer series ppp5′A
(2′p5′A)n for n≥2, whereby n=2 and n=3, for example, represent
the trimer and tetramer of 2-5A, respectively. We also examinedFig. 8. Analysis of 2-5A following in vitro activation of endogenous OAS. (A) Rabbit
reticulocyte lysate (RL) or cell lysates prepared from either CVB1 (8 h pi), HAV/18f (48 h
pi) infected, or IFNβ treated cells were reacted with poly(I):poly(C)-agarose for
activation of endogenous OAS in the presence of ATP (mixture of unlabeled and 32P-
labeled) for subsequent synthesis of 2-5A. Radiolabeled 2-5A products were analyzed
by 7 M urea/20% PAGE (Miele et al., 1991) following treatment with either RNase 1 (A)
or phosphatase (C), or without further treatment (B). The wet gel was exposed to a
phosphorimager screen and scanned using the Typhoon scanner (Molecular Dynamics
Inc., Sunnyvale, CA). The 2-5A oligomer products are identiﬁed.whetherwe could detect synthetase activity in vitro in extracts derived
from either CVB1 (8 h) or HAV/18f (48 h) infected, or IFNβ treated
FRhK-4 cells. As shown in Fig. 8 panel B, the synthesis of 2-5A is
detected in both virus infected (lanes CVB1 and 18f) and IFNβ (lane
IFN) treated cell extracts. Treatment of the post-reaction mixture with
RNase 1 did not alter the pattern of product formation (Fig. 8, panel
A) indicating that activated 2-5OAS from CVB1 or HAV/18f infected,
or IFN-treated, FRhK-4 cells synthesize authentic 2-5A oligomers
that contain a 2′ to 5′ linkage resistant to RNase cleavage. TheCVB1
10 h pi (1) Neat 35
10 h pi (2) Neat 31
(2) 1:2 33
HAV/18f
24 h pi (1) Neat 33
24 h pi (2) Neat 63
(2) 1:2 62
48 h pi Neat 202
72 h pi Neat 137
Clone 1 (1) Neat 0
(2) Neat 0
ds RNA
24 h (1) Neat N640
(1) 1:2 762
24 h (2) Neat N640
(2) 1:2 N730
(2) 1:8 1548
a Extracts from 150 cm2 cells were prepared as lyophilized lysates (see Materials and
methods) and resuspended in 0 pmol/dL 2-5A standard for duplicate analysis (50 μl per
sample analysis) by RIA, yielding a ﬁnal cell monolayer equivalent of 0.9 cm2/μl per
analysis.
b Indicates whether the ﬁrst (1) or second (2) of 2 independent samples was
analyzed.
c Resuspended lysates were analyzed undiluted (neat) or following further dilution
(vol:vol) with 0 pmol/dL 2-5A standard.
d The concentration of 2-5A determined after background (control lysate)
subtraction and correction for dilution.
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A andB) also suggests that these are likely 5′ triphosphorylated species
of 2-5A (Marie et al., 1997; Miele et al., 1991; Sarkar and Sen, 1998;
Rebouillat et al., 1999). To conﬁrm that these species are indeed 5′
phosphorylated, post-reaction mixtures were incubated with alkaline
phosphatase prior to gel electrophoresis. As shown in Fig. 8C, the
mobility of labeled 2-5A synthesized in reticulocyte lysates aswell as in
infected, or IFN-treated, FRhK-4 cell extracts was signiﬁcantly altered
and the discrimination of individual oligomer species was impaired in
a manner consistent with phosphatase mediated cleavage of 5′
terminal phosphates present on 2-5A (Marie et al., 1997). In summary,
the results in Fig. 8 clearly indicate that endogenous levels of 2-5OAS in
either IFN-treated or virus infected FRhK-4 cells are capable of
synthesizing authentic 2-5A in response to activation by dsRNA.
The activator of RNase L, 2-5A, is detected in CVB1 and HAV/18 f infected
cell extracts
Ultimately, the detection of endogenous 2-5A in CVB1 or HAV/18f
infected FRhK-4 cells would provide conﬁrmation that rRNA degrada-
tion in these cells involves activation of the 2′-5′ OAS/RNase L
pathway in a 2-5A dependent fashion. Therefore, detection of
intracellular 2-5A was undertaken by RIA (Sawai et al., 1985) using a
commercially available RIA kit with a simple modiﬁcation to permit
direct detection of 2-5A in heat-denatured clariﬁed lysates obtained
from virus infected cells (see Materials and methods).
As a positive control for 2-5A detection, dsRNA treated FRhK-4 cell
lysates were analyzed for 2-5A levels by RIA since this compound is a
known inducer of 2-5OAS-mediated 2-5A synthesis (Hovanessian and
Justesen, 2007; Minks et al., 1979; Player and Torrence, 1998). As
shown in Table 3, the levels of 2-5A in these cells (762–1548 pmol/dL)
was sufﬁciently high as to require dilution in order to obtain values
falling within the assay range. These results were not surprising given
the ability of dsRNA to both strongly induce expression of OAS and
activate the different isoforms. The detection of 2-5A by RIA was also
applied to lysates from CVB1 or HAV infected cells (Table 3). 2-5AwasFig. 9. Plot of binding ratio versus concentration of 2-5A: graphical comparisons of
the 2-5A standard curve and the effect of control FRhK-4 lysates. (●—●) The plot of
percent bound cpm/total cpm (%B/T) for 0–810 pmol/dL 2-5A standards as the
average (± standard error of the mean) of three independently obtained standard
curves. Performance characteristics as deﬁned by the manufacturer were determined
(and met) for each RIA. Theoretical (▴---▴) and experimental (○---○) binding
curves demonstrating the effect of control, undiluted lysate on the analysis of
samples containing known quantities of 2-5A. Refer to Materials and methods section
for details regarding Fig. 9. For all plots the % B/T equals cpm sample/total cpm×100.reproducibly detected in independent extracts from CVB1 infected
FRhK-4 cells (31–35 pmol/dL,10 h pi). Analysis of diluted CVB1 lysates
gave similar 2-5A values, again supporting the reproducibility of the
analysis. Similar levels of 2-5Awere detected in HAV/18f infected cells
at 24 h pi (33–63 pmol/dL) with an increase in levels observed with
increasing time of infection (202 and 137 pmol/dL at 48 h pi and 72 h
pi, respectively). Most importantly, the detection of 2-5A in CVB1 and
HAV/18f infected cells is consistent with the detection of rRNA
degradation, and therefore RNase L activation, observed in these
infected cells (Figs. 1C and D). 2-5A was not detected, however, in
persistently HAV infected clone 1 cells in which activation of RNase L
does not occur. Therefore, in FRhK-4 cells activation of RNase L appears
to correlate with the synthesis of 2-5A. In summary, the data in Figs. 8
and 9 indicate that both CVB1 and HAV/18f infection are capable of
inducing endogenous OAS enzymatic activity in FRhK-4 cells resulting
in the production of authentic 2-5A, the activator of RNase L activity
observed in these infected cells.
Discussion
The RNase L-mediated cleavage of cellular and viral RNAs is
regarded as an important IFN-regulated antiviral mechanism that
restricts virus replication (particularly picornaviruses) whereby viral
dsRNA can function both as an inducer of IFN expression as well as an
activator of some interferon-stimulated genes (e.g., OAS) that are
critical for downstream activation of RNase L (Jacobs and Langland,
1996; Player and Torrence,1998; Samuel, 2001; Sarkar and Sen, 2004).
The results from previous studies in our laboratory revealed an
apparent activation of RNase L (viz. RNA degradation) during HAV
(cytopathic strain 18f) infection without a requirement for interferon
pretreatment, and in the absence of detectable OAS1 or OAS2 mRNA
expression (Goswami et al., 2004; Kulka et al., 2003). Although the
latter analyses had not been completed for CVB1 infected cells, it
seemed an interesting possibility that similar events may be occurring
during infection with this virus. In other words, despite the
contrasting phenotype of these two viruses, our results suggested
that both viruses were capable of successful replication in apparent
contradiction to the reported sensitivity of picornaviruses to the 2-
5OAS/RNase L antiviral pathway (Bisbal and Silverman, 2007; Jacobs
and Langland, 1996; Player and Torrence, 1998; Samuel, 2001). In the
current investigation, therefore, we sought to determine the relation-
ship of 2-5OAS expression, IFN-dependence, and 2-5A (the activator of
RNase L) synthesis to the activation of the 2-5OAS/RNase L antiviral
pathway during CVB1 infection, thereby determining whether or not
this pathway lacks the functionality as an antiviral mechanism against
CVB1 infection as was previously reported for HAV/18f infected cells.
To facilitate our analysis, it was necessary to develop the tools
appropriate for a more in-depth investigation in the monkey kidney
cell line FRhK-4, such as i) generating afﬁnity puriﬁed anti-OAS
antibodies for detection of OAS protein isoforms 1–3, ii) designing
new PCR primers for targeted ampliﬁcation of rhesus monkey OAS
mRNA isoforms 1–3 (Tables 1 and 2), and iii) adapting existing RIA
technology to the detection of 2-5A in lysates derived from mock,
infected or dsRNA treated cells (Fig. 9 and Table 3).
It is well known that dsRNA plays an important role in the
induction of antiviral pathways such as through activation of the IFN-
regulated 2-5OAS/RNase L and the PKR pathways, as well as induction
of IFN synthesis (Gribaudo et al., 1991; Jacobs and Langland, 1996;
Marie et al., 1990; Minks et al., 1979; Nilsen et al., 1981; Player and
Torrence, 1998). We demonstrated that both CVB1 and HAV/18f are
capable of generating viral dsRNA due to the presence of positive and
negative strand viral genomic RNA generated during replication
(Fig. 6). In addition, RNase Lwas readily detected in CVB1 andHAV/18f
infected cells, as well as dsRNA transfected cells (Fig. 2). Not
surprisingly, therefore, we found that infection with CVB1 or HAV/
18f activates the RNase L pathway in FRhK-4 cells in a manner
179M. Kulka et al. / Virology 388 (2009) 169–184equivalent to that observed for dsRNA treated cells (Fig. 1). However,
activation of endogenous, latent RNase L requires 2-5A synthesized
fromdsRNA-activated 2-5OAS, and previous studies revealed a paucity
of OAS1 and OAS2 expression in FRhK-4 cells (Goswami et al., 2004).
In the current investigation we conducted a rigorous investigation
of the expression of mRNA and protein of all three 2-5OAS isoforms
(Figs. 3 and 4) in either CVB1 or HAV infected, or IFNβ treated FRhK-4
cells by i) RT-PCR using PCR primers designed to speciﬁcally target
rhesus monkey cDNA sequences corresponding to each of the three 2-
5OAS isoforms (Table 2), and ii) western blot analysis using afﬁnity
puriﬁed rabbit antiserum capable of detecting all three isoforms of 2-
5OAS protein (Chebath et al., 1987a; Table 1). We found that FRhK-4
cells are not inherently defective for synthesis of 2-5OAS since there is
an increase in the level of all three isoforms of 2-5OAS mRNAs
following 2 and 12 h IFNβ treatment. However, an increase in the level
of OAS2 and OAS3 proteins is observed only at 12 h IFNβ post-
treatment. The level of OAS1 protein post-IFNβ treatment did not
increase at all to a level sufﬁcient for detection by western blot
analysis. Importantly, analysis of OAS expression following either
CVB1 or HAV/18f infection revealed an absence of induction in the
level of OAS1 or 2 proteins or their respective mRNAs. In contrast,
OAS3 mRNA and protein were observed in both uninfected and
infected cells indicating that this isoform is constitutively expressed in
FRhK-4 cells and continues to be present throughout infection with
either CVB1 or HAV. It has been previously reported that cellular levels
of individual 2-5OAS isoforms can vary among cell lines and these
levels can change in response to either IFN treatment or virus infection
(Chebath et al., 1987a, 1987b; Flodstrom-Tullberg et al., 2005; Geiss et
al., 2001; Hovanessian et al., 1987, 1988; Rebouillat et al., 2000;
Takahashi et al., 2002; Witt et al., 1993; Zhu et al., 1998). However, the
predominance of OAS3 expression over OAS isoforms 1 and 2 in FRhK-
4 cells, particularly in the context of RNase L activation by CVB1 and
HAV/18f, was intriguing given that the contribution of OAS3 to
activation of RNase L (viz. 2-5A synthesis) is currently unknown.
In order to investigate whether endogenous OAS levels are
enzymatically functional (i.e., activated by dsRNA), cell extracts from
virus infected or IFN-treated cells were used in an in vitro assay. 2-5A
product formationwas analyzed by urea-PAGE as previously described
(Miele et al., 1991; Sarkar and Sen, 1998) and compared to products
generated in vitro from rabbit reticulocyte lysate (RL) which is known
to synthesize authentic 2-5A in response to dsRNA (Fig. 8). The results
of our analyses indicate that the products synthesized by reticulocyte
lysate (RL), IFN-treated cell extracts and virus infected cell extracts
were qualitatively identical in nature after alkaline phosphatase and
RNase 1 digestion. Thus, the synthesized products contain both an
RNase resistant 2′-5′ linkage as well as phosphatase sensitive terminal
phosphates and represent authentic 2-5A. The differences in the
relative size and amount of oligomeric species generated from IFN-
treated versus virus infected cells are likely due to the elevated levels
of all three OAS isoforms following interferon treatment in FRhK-4
cells (Figs. 3A and 4B) compared to the lower levels of the single
isoform OAS3 present in CVB1 or HAV/18f infected cells (Fig. 3, panels
C and D; Fig. 4, panels C and D). These differences are consistent with
previous reports indicating that OAS2, which we detected in the IFN-
treated but not virus infected FRhK-4 cells, is capable of synthesizing a
greater abundance of longer 2-5A species (Hovanessian and Justesen,
2007; Marie et al., 1997; Sarkar and Sen, 1998). Investigators have
questioned the role of OAS3 in the activation of RNase L due to its
synthesis primarily of 2-5 dimers that do not activate RNase L
(Hovanessian and Justesen, 2007; Sarkar and Sen, 2004). However,
activated OAS3 does not exclusively synthesize 2-5A dimers, as the
range of oligomer size has been shown to be from 2 to 10 bases
(Hovanessian et al., 1988; Marie et al., 1997; Rebouillat et al., 1999;
Sarkar and Sen,1998). Indeed, in our study OAS3 is essentially the only
isoform detected concomitant with the in vitro production of a range
of 2-5A species from either CVB1 or HAV/18f infected cells (Fig. 8).Furthermore, the analysis of endogenous 2-5A (by RIA) in extracts
from these infected cells also reveals the synthesis of authentic 2-5A
(Table 3). Given that activation of RNase L is observed in these infected
cells and 2-5A dimer is not an activator of RNase L, it is reasonable to
conclude that synthesis of active 2-5A (i.e., trimer and larger) is
occurring during CVB1 and HAV/18f infection and OAS3 is the likely
generator of these active species. These results are signiﬁcant as we
are unaware of any published reports of an activated 2-5OAS/RNase L
pathway in the presence of only OAS3 expression.
At present, we are unable to explain why CVB1 infected cells
contain lower levels of 2-5A and synthesize 2-5A at a lower rate in
vitro, compared to HAV infected cells (Table 3; Fig. 8), although RNA
cleavage is readily apparent. One reason could be the general status of
CVB1 infected cells, compared to HAV infected cells, particularly in
regard to the percentage of cells undergoing cpe (cytopathic effect)/
apoptosis and shut-off of host protein synthesis. At 8 h pi CVB1
infected cells show 100% cpe as opposed to only 10–20% cpe in HAV/
18f infected cells after 48 h. Also, virus-mediated host (protein) shut-
off occurs in CVB1 but not HAV/18f infected cells. The result of either
process could affect a reduction in the level of functional 2-5OAS
available for induction of 2-5A synthesis. Indeed, we observed a
reduction in the level of detectable OAS3 following CVB1 infection
compared to either HAV/18f infected or IFNβ treated FRhK-4 cells (Fig.
3). Alternatively, the activity of an endogenous 2′-5′ phosphodiester-
ase (Kubota et al., 2004), a potential regulator of intracellular 2-5A
levels, may be elevated following CVB1 infection.
FRhK-4 cells are permissive for CVB1 and HAV/18f replication and
these viruses can be grown to high titers in this cell line (Kulka et al.,
2003; Goswami et al., 2004). It is currently unknown why their
replication appears unabated in these cells despite the activation of
the antiviral pathway 2-5OAS/RNase L. Perhaps in FRhK-4 cells RNase
L is sufﬁciently activated to initiate rRNA cleavage but cleavage of viral
genomic RNA may be restricted due to its protective interaction with
viral/host proteins. Alternatively, 2-5OAS/RNase L pathway activa-
tion, as measured by onset of rRNA degradation (N7–8 h pi for CVB1;
≥16 h pi for HAV/18f), may occur too late in the replication cycle to
have any signiﬁcant effect on viral RNA integrity. Ultimately, we have
demonstrated that these picornaviruses are not inhibited by an
activated 2-5OAS/RNase L antiviral pathway suggesting that picorna-
virus sensitivity might be species dependent. We have not investi-
gated whether other antiviral mechanisms, such as the dsRNA-
activated protein kinase (PKR) or RNA editing, are activated during
either CVB1 or HAV/18f infection in these cells. Many of these
mechanisms, however, are generally regarded as IFN-inducible
(Samuel, 2001; Sarkar and Sen, 2004). In this regard, we have no
indication that IFN is produced during CVB1 infection (Figs. 5A and B)
and IFN pretreatment has no apparent effect on virus replication or
viral protein expression (Fig. 7B). This suggests that the other IFN-
regulated antiviral mechanisms are either not activated, or CVB1 and
HAV/18f replication are unaffected by their activity. Alternatively, it
remains a possibility that activation of other antiviral mechanisms
may occur late in CVB1 infection in the absence of IFN. If this were
true, however, then one would conclude that a putative late activation
of another antiviral pathway also has little relevance in limiting the
replication of these viruses.
We do not knowwhy HAV/HM175 clone 1 is unable to activate the
2-5OAS/RNase L pathway even after several months of persistent
infection (Fig. 1). There is no indication of any unusual processing of
RNase L protein when comparing dsRNA treatment to infection with
either CVB1 or HAV (18f or clone 1) in FRhK-4 cells (Fig. 2) and OAS3
protein is constitutively expressed at levels similar to those detected
in uninfected FRhK-4 cells (Fig. 3). The potential for viral dsRNA
formation exists in both CVB1 and HAV infected cells since viral
negative strand RNA is detected by strand speciﬁc RT-PCR (Figs. 6,
panels A and B), yet, only in CVB1 and HAV/18f infected are both 2-5A
synthesis and RNase L activation readily detected. Perhaps cellular or
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infected cells (Bisbal and Silverman, 2007; Han et al., 2007; Samuel,
2001; Townsend et al., 2008). Alternatively, we have observed that the
lack of detectable 2-5A synthesis/2-5OAS activation (Table 3) in clone
1 infected cells correlates with low levels of viral negative strand RNA
[e.g., at 28 days pi (Fig. 6A)], in contrast to the relatively higher levels
of viral negative strand RNA and 2-5OAS activation observed during
either CVB1 or HAV/18f infection. In addition, the onset of RNase L
activity (viz. rRNA degradation) correlates with the virus replication
rates where CVB1 is the fastest, and clone 1 is the slowest, of the three
viruses tested. Therefore, viral dsRNA levels during clone 1 infection
may simply be insufﬁcient to activate any OAS present. It is interesting,
however, that the activation parameters of OAS3 have been shown to
be different from that of OAS2, at least in vitro (Hovanessian and
Justesen, 2007; Hovanessian et al., 1988, 1987; Marie et al., 1990, 1997;
Player and Torrence, 1998; Sarkar and Sen, 1998). For example, these
two isoforms differ in their concentration dependence for minimal
and maximal activity whereby OAS3 requires about 10 to 100-fold
lower concentrations of dsRNA than OAS2 (Hovanessian et al., 1988;
Marie et al., 1997; Rebouillat et al., 1999; Sarkar and Sen, 1998). If a
similar dsRNA concentration dependence for OAS activation occurs in
vivo, then the contribution of OAS3 to the activation of RNase L might
be unapparent in cells infected with rapidly replicating picorna-
viruses, such as EMC, Mengo, poliovirus or CV, when OAS2 and/or
OAS1 are present. As suggested by the results of this investigation, we
believe the biological relevance of OAS3 resides in its potential for
activation by slower replicating picornaviruses such as HAV/18f.
FRhK-4 cells are functionally responsive to either IFNα or IFNβ
treatment (Figs. 3 and 4; Goswami et al., 2004; Kulka et al., 2003) yet
we have observed that pretreatment with IFNβ does not inhibit either
virus replication (at least at highmoi) or viral protein synthesis (Fig. 7),
nor does it augment RNase L activity in CVB1 infected (Fig. 7) or
HAV infected cells (Goswami et al., 2004). This is in contrast to
previous reports on the augmented activation of the RNase L
pathway and subsequent inhibition of EMC virus (a picornavirus)
growth and following IFN pretreatment (Cayley et al., 1982;
Silverman et al., 1982). Given that onset of rRNA degradation is
fairly rapid during CVB1 infection; we interpret our results to
suggest that sufﬁcient 2-5A is already synthesized for maximal
activation of RNase L in these cells during CVB1 infection. As for
HAV/18f, the onset of rRNA degradation occurs later in infection for
this slower growing virus, and viral dsRNA may not reach levels
sufﬁcient to activate increased levels of OAS, particularly OAS2 and/
or OAS1. For infection with either virus, therefore, any IFN-mediated
increase in OAS levels would have little net effect on RNase L
activity. We also conclude that there is no signiﬁcant synthesis of
IFNβ in response in either CVB1 or HAV/18f infected FRhK-4 cells
(Fig. 5; Goswami et al., 2004; Kulka et al., 2003), and the fact that
both viruses replicate to high titer in these cells whether infected at
low or high moi is consistent with the absence of IFN synthesis. It is
possible that virus-mediated mechanism(s) responsible for the
inhibition of IFN synthesis in other picornavirus infected cells may
also exist in CVB1 infected FRhK-4 cells (Barral et al., 2007; Brack et
al., 2002; Fensterl et al., 2005; Goswami et al., 2004; Yang et al.,
2007). In particular, the proteosome-/caspase-dependent cleavage of
MDA5 suggested as responsible for the absence of interferon
synthesis following infection with either poliovirus or rhinovirus
1a (Barral et al., 2007) might be relevant for CVB1 and HAV/18f
since infection with these viruses activates the caspase-mediated
apoptotic pathway in FRhK-4 cells (Goswami et al., 2004; Goswami
and Kulka, unpublished).
The activation of RNase L has been implicated in the induction of
apoptosis (Castelli et al., 1988; Rusch et al., 2000; Zhou et al., 1997),
although the mechanisms by which the two processes are connected
are not well understood. Based on the appearance of caspase-3 and
PARP cleavage, TUNEL positive cells, and cytoplasmic DNA laddering,we concluded that the cytopathogenicity during HAV/18f infection in
FRhK-4 cells was due to the induction of apoptosis by a mechanism
involving activation of RNase L (Goswami et al., 2004). Interestingly,
we also obtained similar results following CVB1 infection in these cells
(Goswami and Kulka, unpublished). It seems plausible that activation
of rRNA cleavage and induction of apoptosis may either be necessary
for facilitating CVB1 and/or HAV/18f replication in FRhK-4 cells, or
alternatively these cellular processes may be inhibited until the virus
(es) can complete their replication cycle due to the potential for
detrimental effects on replication. Indeed, either scenario seems likely
since activation of RNase L occurs late in the respective life-cycles of
these viruses (7–8 h pi for CVB1; 16–24 h pi for HAV/18f) and growth
of these two viruses continues before apoptosis is induced (8–10 h pi
for CVB1; 48 h pi for HAV/18f). The relationship between apoptosis
and the growth/replication of CVB1 and HAV in permissive cells
continues to be the focus of ongoing research in our laboratory.
Since we can detect the expression of 2-5OAS, the activation of
endogenous OAS (with dsRNA) with synthesis of authentic 2-5A, and
the presence of endogenous cellular 2-5A concomitant with activation
of RNase L during either CVB1 or HAV/18f infection in FRhK-4 cells, it
is reasonable to conclude that the 2-5OAS/RNase L pathway is
activated in these cells. Our results also indicate that i) the 2-5OAS/
RNase L pathway plays a minimal, if any, role in the inhibition of CVB1
or HAV/18f replication, and ii) IFN may play only a limited role as an
antiviral compound in FRhK-4 cells. Most importantly, these results
suggest that constitutive levels of OAS, in particular OAS3, may be
sufﬁcient for synthesis of 2-5A and activation of RNase L in FRhK-4
cells during virus infection, although not all virus infections (e.g.,
HAV/HM175 clone 1) will trigger this response. Our results suggest a
need for further investigation into picornavirus replication/dsRNA
formation and OAS3 activation in FRhK-4 cells compared to other
monkey and human kidney cell lines.
Materials and methods
Cells and viruses
Coxsackievirus B1 strain Conn-5 (CVB1), HAV strain 18f (HAV/18f)
and HAV HM175/clone 1 (clone 1) were obtained from ATCC
(Manassas, VA). The 18f strain of HAV is a rapidly replicating
apoptosis inducing variant, originally derived from a cell culture
adapted wild-type strain HM175 (Cromeans et al., 1989; Lemon et al.,
1991) while the clone 1 strain of HAV is a non-cytopathic cell culture
adapted strain derived from wild-type HM175 (Daemer et al., 1981).
The FRhK-4 (fetal rhesus monkey kidney) cell line was obtained from
Dr. G. Kaplan (Center for Biologics Evaluation and Research, FDA) and
cultured in MEM supplemented with pyruvate and non-essential
amino acids (Invitrogen, Gibco Cell Products, Carlsbad, CA) contain-
ing 5% heat-inactivated fetal bovine serum. The 293 (human kidney)
cell line purchased from ATCC was cultured in complete MEM (as
above) except with 10% heat-inactivated fetal bovine serum. HAV
stocks were prepared in FRhK-4 cells essentially as described by
Dotzauer et al. (2000), and CVB1 stocks were prepared in FRhK-4 cells
based on the method described for CVB3 by Zaragoza et al. (1997)
using a 14–16 h incubation period. The establishment of persistently
HAV HM175/clone 1 infected cells, as well as procedures for acute
infectionwith CVB1,18f, and clone 1 virus and virus titration have been
described previously (Kulka et al., 2003; Goswami et al., 2004).
Antibodies
Mouse monoclonal antibody (mAb) to human RNase L was
obtained as a generous gift from Dr. R. H. Silverman (Cleveland Clinic
and Foundation, OH) for use in initial analyses and subsequently
obtained from Abcam (Cambridge, MA). In western blot analysis, this
mAb detects human (Rusch et al., 2000) and monkey (Goswami, B.
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antibody was purchased from Sigma-Aldrich (St. Louis, MO). Rabbit
anti-phosphoY701-STAT-1 and rabbit anti-STAT-1 were purchased from
Cell Signaling Technologies (Beverly, MA). Coxsackievirus B1 (horse)
antiserumwas purchased from ATCC (Manassas, VA) that reacts with
a 33 kDa (apparent molecular weight) protein from CVB1, but not
mock, infected cell extracts (Fig. 1A) consistent with the size of CVB
virus capsid protein VP1 (Haarmann et al., 1994); it is not cross-
reactive with HAV proteins in western blot analysis (data not shown).
Polyclonal rabbit antiserum to HAV capsid VP1 has been previously
described by Kulka et al. (2003). Goat anti-rabbit and goat anti-mouse
horseradish peroxidase (HRP)-labeled secondary antibodies were
purchased from Pierce Biotechnology Inc. (Rockford, IL) and goat anti-
horse HRP-labeled secondary antibody was purchased from Rockland,
Inc (Gilbertsville, PA). Polyclonal antibody to human 2-5OAS was
obtained fromNew Zealandwhite rabbits immunizedwith a synthetic
peptide CEKYLRRQLTKPRPVILDPAD. This peptide sequence was based
on peptide B described by Chebath et al. (1987a). The N-terminal C
(cysteine) was included in the peptide sequence to facilitate coupling
to a carrier protein KLH (keyhole limpet hemocyanin). In Table 1, a
comparison of amino acid sequences within each OAS isoform
homologous to the immunizing peptide is listed for both human and
rhesus monkey 2-5OAS proteins. The immunizing peptide incorpo-
rates the conserved N-terminal amino acids of exon E of human 2-
5OAS andwas shown to be capable of detecting differential expression
of all three isoforms of 2-5OAS among a variety of cell lines (Chebath
et al., 1987a). The peptide was synthesized at FDA (Division of
Virulence Assessment, CFSAN) and KLH-conjugated using the Imject
Maleimide Activated mcKLH Kit (Pierce) according to manufacturer's
instruction. Collection of pre-immune serum, immunizations and
challenges with KLH-conjugated peptide in adjuvant, hyperimmuni-
zation with free peptide and immune serum collection were as
previously described (Kulka et al., 2003). All animal studies were
conducted in compliance with the Guide for Care and Use of
Laboratory Animals under an approved IACUC protocol. Preliminary
studies using hyperimmune anti-2-5OAS whole antiserum against
dsRNA treated or control FRhK-4 cell protein extracts in western blot
analysis revealed a strong induction of OAS2 and OAS3 that follows
dsRNA treatment. In the absence of dsRNA treatment, only OAS3 was
detected, albeit at low levels (data not shown). Results of western blot
analysis were completed following puriﬁcation of this polyclonal
serum and revealed a signiﬁcant improvement in the sensitivity of
OAS detection (data not shown). Afﬁnity puriﬁed antiserum was
therefore used in all subsequent analyses presented in the current
investigation. Puriﬁcation of anti-2-5OAS antiserum by afﬁnity
chromatography was accomplished using immunizing peptide
coupled-agarose (SulfoLink Kit, Pierce) according to manufacturer's
instructions.
Virus infection and IFNβ treatment
FRhK-4 cells were mock, HAV/18f or CVB1 infected at an moi of 8–
10 (60 or 90min adsorption for CVB1 or HAV/18f, respectively) for the
indicated times at 37 °C in growth media containing 1% heat-
inactivated FBS. Cell cultures were harvested by scraping, and washed
(cold PBS) cell pellets were obtained for subsequent nucleic acid,
protein or 2-5A extraction (Kulka et al., 2003; Goswami et al., 2004).
Persistently HAV HM175/clone 1 infected FRhK-4 cells were con-
tinuously cultured (Kulka et al., 2003; Goswami et al., 2004) and used
to obtain cell pellets (100–150 days post-infection [pi]) for nucleic
acid, protein or 2-5A extraction as described for mock and acutely
infected cells. Routinely cultured FRhK-4 cells were the source of
uninfected, non-treated cell pellets and extracts described in this
study. Interferon-β (Sigma Chemicals, St. Louis, MO) treatment
(1000 U/ml) was added to cell cultures in complete growth media
and cells were incubated for the times indicated.Double-stranded (ds) RNA transfection
FRhK-4 cells were transfected with 25 μg/ml dsRNA [poly(I):poly
(C), Amersham] using 20 μg/ml lipofectin (Invitrogen) based on
manufacturer's protocol for transfection with DNA. Parallel mock
transfections (i.e., without dsRNA) served as negative controls. Cells
were harvested at 24 h post-transfection for subsequent extraction of
RNA or protein isolation, or 2-5A.
RNA isolation, rRNA degradation analysis, and protein extracts
Total cytoplasmic RNA was isolated for the analysis of rRNA
degradation by agarose gel electrophoresis as described previously
(Kulka et al., 2003; Goswami et al., 2004). Similarly extracted RNAwas
also used for the analysis of 2-5OAS, RNase L or IFNβmRNA expression
by RT-PCR. RNA concentrations were calculated from the absorbance
measured at 260 nm. Protein extracts were obtained as total cell
(soluble) lysates from mock or virus infected cells using RIPA buffer
(plus protease and phosphatase inhibitors) as previously described
(Kulka et al., 2003). Fractions were stored in aliquots at −70 °C.
Protein concentrations were determined using the BCA-200 Protein
Assay (Pierce) according to the manufacturer's instructions.
Reverse transcription and PCR
Total cytoplasmic RNAs were subjected to DNase I digestion,
phenol:chloroform:isoamyl alcohol (Invitrogen) extraction and etha-
nol precipitation prior to reverse transcription (1 μg RNA per reaction)
with AMV reverse transcriptase (RT) using an oligo(dT)15 primer (2 μg
per reaction) as previously described (Goswami et al., 1994, 2004). For
PCR ampliﬁcation of OAS isoforms, 4 μl of the cDNA preparation was
ampliﬁed using Taq polymerase (Promega) in a 50 μl PCR reaction
containing 150 μM dNTPs with 50 pmol of each (sense and antisense)
primer, cycling parameters and optimal magnesium chloride concen-
trations as indicated in Table 2. PCR ampliﬁcation of RNase L was
completed as described for OAS except using an annealing tempera-
ture of 60 °C, a 180s [72 °C] extension, 2.5mMMgCl2, for 30 cycles, and
5′ CACCATGGAGAGCAGGGATCATAAC 3′ and 5′ TGAACTCCAGCAAATC
AGTCC 3′ as the sense and antisense primers, respectively. These
primers target nucleotide sequences which ﬂank the entire coding
region of RNase L and share identity with both the human (Genbank
accession L10381) and Rhesus monkey (Genbank accession
EF467993) sequences to generate a 2.2 kb amplicon from either
species. Following RT, PCR ampliﬁcation of IFNβ (35 cycles) using a
primer pair speciﬁc for IFNβ at an annealing temperature of 56 °C was
based on Goswami et al., 2004 to generate a 552 bp amplicon (Brack et
al., 2002) and of β-actin (2.5 mM MgCl2, 30 cycles) using a
commercially available primer pair (Promega) was based on cycling
conditions described for OAS except using an annealing temperature
of 65 °C to generate a 285 bp amplicon. Except where noted, all PCR
primers were obtained from Loftstrand Labs, Ltd (Gaithersburg, MD).
PCR products were analyzed by agarose gel electrophoresis (Goswami
et al., 2004). The identities of ampliﬁed OAS and RNase L were
conﬁrmed by sequence analysis (Amplicon Express, Pullman, WA).
Strand selective RT was used to demonstrate the presence of viral
positive and negative strand RNA (Chehadeh et al., 2000). The
following primer sequences were used for these experiments: HAV
sense: 5′ CCGTTTGCCTAGGCTATAGGCTA 3′; HAV antisense: 5′ CAGC-
TCCATGCTAATCATGGAGT 3′; CVB1 sense: 5′ CCCCTGAATGCGGC-
TAATCC 3′; CVB1 antisense: 5′ GCCAMTCCAATARCTATATG 3′, where
M and R represent A or C, and A or G, respectively.
PAGE and Western blot analyses
Equal amounts of protein (RIPA) extracts were adjusted to
equivalent volumes in denaturing sample buffer containing 100 mM
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12% Bis–Tris gels using MOPS-SDS running buffer (Invitrogen)] under
reducing conditions, followed by electrophoretic transfer onto
nitrocellulose in 0.65×Transfer Buffer (Invitrogen) containing 10%
methanol. Western blot analysis was performed as previously
described for antibodies to HAV capsid protein VP1, and actin (Kulka
et al., 2003; Goswami et al., 2004). Primary antibodies were diluted
(anti-CVB1 at 1:1500; anti-VP1 at 1:1400; anti-OAS at 1:270; anti-
actin at 1:1750; anti-RNaseL at 1:1000) in TBS-T containing 5% nonfat
dry milk [NFDM] or 5% BSA (anti-STAT and anti-phosphoY701-STAT1 at
1:1000) for overnight incubation at 4 °C. Secondary antibody-HRP
conjugates were used at a 1:10,000 dilution in TBS-T/5% NFDM for 1 h
incubation at RTand subsequent detection by chemiluminescencewas
as previously described (Kulka et al., 2003).
35S-labeling and SDS-PAGE
FRhK-4 cells were grown in 25 cm2 ﬂasks and 12–14 h prior to virus
infection treated or not with growth media containing 1000 U/ml
human IFNβ. Cells were infected with CVB1 as described above under
“virus infection” and labeled for 2 h beginning at 6 h pi with 50 μCi/ml
of 35S-methionine (GE Life Sciences) in methionine-free medium
supplemented with 5% dialyzed FBS (ICN) following a 30 min pre-
incubation in methionine-free medium. Cells were collected by
scraping, washed once with PBS and the pellets lysed in 400 μl RIPA
buffer containing protease inhibitors (Sigma-Aldrich). Lysates were
clariﬁed by centrifugation (10 k ×g, 10 min, 4 °C), 10% TCA precipitable
incorporationwas measured using 10 μl of clariﬁed lysate diluted 1:10
in RIPA buffer, and protein concentrationwas determined as described
under “RNA and protein extracts.” Labeled proteins (200,000 cpm per
lane) were subjected to SDS-PAGE as described under “PAGE and
Western blot analysis”, the gel was ﬁxed and treated with Amplify for
signal enhancement according to manufacturer's instructions (Amer-
sham Pharmacia Biotech Inc., Piscataway, NJ), then soaked in water
containing 20% ethanol and 10% glycerol for 30 min prior to overnight
drying between cellophane sheets (Diversiﬁed Biotech, Boston, MA).
The dried gel was exposed to a phosphorimager screen (4–10 days)
then scanned using the Typhoon scanner (Molecular Dynamics Inc.,
Sunnyvale, CA).
In vitro synthesis and analysis of 2-5A
32P-labeled 2-5A was synthesized following the incubation of cell
extracts absorbed to poly(I):poly(C)-agarose in the presence of α-32P
ATP. 2-5A synthesized from nuclease treated rabbit reticulocyte lysate
(Promega) absorbed to poly(I):(C)-agarose was used as standard. Cell
extracts were prepared from interferon-β treated (1000 U/ml, 16 h),
uninfected or virus infected cell pellets lysed in buffer (20 mMHEPES,
pH 7.4, 10 mM KCl, 1.5 mM MgCl2, 7.5 mM 2-mercaptoethanol)
containing protease inhibitor cocktail (EDTA-free, Pierce) and 0.5%
NP40, following mild Dounce homogenization. The lysate was
centrifuged at 15,000 ×g for 15 min, the supernatant was removed
and adjusted to10% in glycerol supplemented buffer and stored at
−70 °C.
For synthesis of 2-5A, cell extracts (200 μl, approximately
50 μg protein) were adjusted to 140 mM KCl, 5 mM MgCl2,
7.5 mM 2-mercaptoethanol containing EDTA-free protease inhibitor
cocktail for incubation with poly(I):(C)-agarose. Eighty microliters
of a 50% poly(I):poly(C)-agarose suspension, washed thoroughly
with a solution of 20 mM HEPES, pH 7.4,140 mM KCl, 5 mM
MgCl2 and 7.5 mM 2-mercaptoethanol, was used to obtain a 40 μl
(packed) agarose pellet for resuspension with 200 μl of cell extracts.
The suspension was mixed gently at room temperature for 15 min,
centrifuged and the packed resin washed three to four times with
the binding buffer to remove unbound proteins. The washed pellets
were incubated with equal volumes of a reaction mixture containing40 mM HEPES, 20 mM MgCl2, 50 mM KCl, 5 mM DTT, 2 mM ATP, 20%
glycerol, and 2 μl 32P labeled ATP (GE Amersham, 3000 Ci/mMol,
10 mCi/ml). Rabbit reticulocyte lysate was diluted with an equal
volume of the binding buffer and 200 μl (0.5 to 1mg protein) was used
for each 40 μl packed volume of the poly(I):poly(C)-agarose. The
washed pellets were incubated as described above for cell extracts.
After overnight incubation at 30 °C, the reactions were stopped by
heating at 95 °C for 5 min, and centrifuged. Reaction products (2 μl)
were analyzed by 7 M urea, 20% polyacrylamide gel electrophoresis
essentially as described by Miele et al. (1991) with or without
treatment with bacterial alkaline phosphatase (TaKaRa, 0.4 U/μl).
The gel was exposed to a phosphorimaging screen after removing the
glass plate fromone side, andwrapping in Saranwrapwhile still on the
opposing glass plate, and the screen was scanned in a Typhoon 8600
scanner.
Analysis of cellular 2-5A levels by radioimmunoassay (RIA)
Soluble cell lysates were prepared from FRhK-4 cells grown in
75 cm2 ﬂasks for analysis of endogenous levels of 2-5A. Duplicate
culture ﬂasks were mock, CVB1 or HAV/18f infected, or control or
dsRNA transfected, for the indicated times to obtain pooled, washed
pellets. Routinely sub-cultured and persistently HAV HM175/clone 1
infected FRhK-4 cell pellets were similarly obtained from duplicate
culture ﬂasks. Brieﬂy, cell (150 cm2 equivalent) pellets were
resuspended in 300 μl cold DNase/RNase free water (Gibco Life
Technologies, Carlsbad, CA), heated to 98 °C for 15–20 min, immedi-
ately chilled in an ice-water bath for 10 min, and centrifuged (4 °C,
40 min, 20K ×g) to obtain clariﬁed soluble cell lysates. Following
30 min (minimum) freezing at −70 °C, lysates were lyophilized to
dryness (and stored at−70 °C when necessary) prior to resuspension
in the 0 pmol 2-5A standard immediately before analysis of 2-5A
levels by RIA.
Analysis of 2-5A levels was accomplished using the Synthetase (2-
5A) RIA kit (ALPCO Diagnostics, Salem, NH) adapted to directly
measure 2-5A in heat-denatured clariﬁed cell lysates prepared as
described above. 2-5A present in the resuspended cell extracts or
synthesized by poly (I):(C)-activated serum OAS enzymes (positive
control; synthetase activity provided by manufacturer) is measured
following the addition of I125-2-5A for competitive binding to anti-2-
5A antibody and immune-complex formation with secondary anti-
body. A standard curve is generated using 0–810 pmol authentic 2-5A
standards added to post-poly (I):(C)-activated negative control serum
samples (serum lacking any synthetase activity). Similarly, resus-
pended lysates are added to post-poly (I):(C)-activated negative
control sera. The antibodies, control sera, cold (standards) and
radiolabeled 2-5A are supplied with the kit. The 2-5A standards
(10–810 pmol/dL) contain the triphosphate 2-5A trimer and are also
provided with the kit. The anti-2-5A serum reacts most efﬁciently
with the 5′ triphoshorylated trimeric and tetrameric forms of 2-5A
and with signiﬁcantly lower binding efﬁciencies for the 5′ tripho-
sphate dimer and 5′ monophosphate trimer. It also reacts with non-
phosphorylated trimer, albeit with even lower binding efﬁciencies
than for themonophosphate trimer, and very low efﬁciency of binding
for 3′-5′ linked oligomers, ATP, ADP, AMP and adenosine. Representa-
tive examples of these binding efﬁciencies may be found in Sawai et al.
(1985).
For each independent assay, a standard curve (plotted as the
binding ratio versus 2-5A concentration) was generated using
manufacturer provided 2-5A (data not shown). A 2-5OAS (positive)
control was also provided by the manufacturer and included in each
assay. In addition, to facilitate the determination of lysate concentra-
tions of 2-5A (by extrapolation), the standard curve and positive
control also provided a metric for evaluation of assay performance
based on the manufacturer's speciﬁcations. In summary, all standard
curves gave essentially overlapping plots and positive control values
183M. Kulka et al. / Virology 388 (2009) 169–184were within the range indicated by the manufacturer. To illustrate
assay reproducibility, the % B/T plotted as the average±standard
error of themean (SEM) (with an SEM range of 0.6–1.6) of all standard
curves is shown in Fig. 9 (upper curve). Preliminary studies indicated,
however, that control lysate alone (i.e., from untreated, uninfected cell
extracts) contributes background binding to the RIA (data not shown).
To determine whether this background would interfere with the
capability of determining 2-5A levels by this method of analysis, two
graphical analyses were completed for comparison of their plot
characteristics. First, using the standard curve, a theoretical binding
curve was generated where i) the percent B/T obtained for control
lysate alone was plotted as 0 pmol/dL 2-5A, and ii) the percent B/T
predicted for control lysate with increasing concentrations of 2-5A
(10–810 pmol/dL) was determined from the standard curve and
plotted against the concentration of 2-5A. Second, an experimental
binding curve was generated whereby lyophilized control lysates
were resuspended with the 0–810 pmol/dL 2-5 A standards and the
percent B/T determined and plotted versus the known input of 2-5A.
As shown in Fig. 9 (lower plots), both the theoretical and
experimental plots are essentially super-imposable indicating that
the lysate milieu i) does not interfere with the capability of
determining 2-5A levels by this method of analysis, and ii) can be
treated as assay background (i.e., 0 pmol/dL 2-5A) for subtraction
from experimental values. However, since the change in slope for the
control lysate plot is less than that for the standard curve plot over the
10–30 pmol/dL range, we conservatively assigned 30–810 pmol/dL as
the assay range for cell lysate analysis rather than 10–810 pmol/dL as
given by the manufacturer. Additional performance characteristics
were determined (and met) for each RIA. Based on these results we
concluded that the assay is both reliable and reproducible.
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